Paxlovid Saves Older CoVid Patients

Vidcast:  https://youtu.be/VDxmwi5jtFo

 

Strategic use of the protease-inhibitor nirmatrelvir, a key component of the Paxlovid cocktail, for those CoVid patients 65 years and older cuts their rate of hospitalization by nearly three-quarters.  Israeli researchers now publish their data in the New England Journal of Medicine after comparing the outcomes of 3902 CoVid patients treated with the protease inhibitor during the Omicron period.  The control group of 105,352 did not receive the drug.

 

The older treated patients clocked a 73% reduction in CoVid-related hospitalizations.  More significantly they enjoyed a 79% lower risk of death.  The middle-aged patients 40 through 64 years of age saw no benefit from the nirmatrelvir in terms of hospitalization or death.

 

These finalized results indicate that seniors contracting CoVid should definitely receive Paxlovid despite an incidence of rebound.

 

https://www.nejm.org/doi/full/10.1056/NEJMoa2204919

 

#CoVid #nirmatrelvir #paxlovid #seniors #hospitalization #death